NEW YORK – BioSpyder Technologies on Wednesday filed a civil action in US District Court for the Northern District of California seeking a declaratory judgement that the firm's TempO-Seq gene expression profiling assay does not infringe a patent held by HTG Molecular Diagnostics.
BioSpyder's actions relates to US Patent No. 8,741,564 held by HTG covering a quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements.
The Carlsbad, California-startup firm said that HTG has repeatedly and baselessly asserted that BioSpyder has infringed the '564 patent.